Results 61 to 70 of about 150,694 (118)

Association of DPYD rs4294451, plasma uracil concentration, and sex with 5-fluorouracil exposure in patients with gastrointestinal cancer. [PDF]

Cancer Chemother Pharmacol
Brooks GA, Ness DB, Hourdequin KC, Ripple GH, Amin M, Lord-Halvorson S, Khan WA, Deharvengt SJ, Busque V, Dragnev KH, Zhao W, Tosteson TD, Lewis LD.   +12 more
europepmc   +1 more source

Pharmacokinetics of 5-Fluorouracil in Patients Treated With Capecitabine Carrying the c.1236G>A <i>DPYD</i> Variant Allele. [PDF]

JCO Precis Oncol
Heersche N, Knikman JE, Deenen MJ, Rosing H, van Schaik RHN, Beijnen JH, Schellens JHM, Gelderblom H, Guchelaar HJ, Swen JJ, Cats A, Mathijssen RHJ, Jacobs BAW.   +12 more
europepmc   +1 more source

Do Socio-Economic Determinants Influence DPYD Testing? A Real-World Study of 1478 Cancer Patients Receiving Fluoropyrimidine Chemotherapy. [PDF]

Med Sci (Basel)
Baraka B, Mathiyalagan N, Al-Ani M, Mohindru G, Semple T, Divyateja H, Figueredo G, Quinlan P, Aithal GP, Madhusudan S.   +9 more
europepmc   +1 more source

Cost-effectiveness of DPYD genotyping prior to capecitabine administration for metastatic breast cancer. [PDF]

Breast Cancer Res Treat
Chiddarwar T, Blaes A, Kuntz K.
europepmc   +1 more source

Dihydropyrimidine dehydrogenase modulates immune response to checkpoint inhibition in mismatch repair deficient/microsatellite instability-high colorectal cancer. [PDF]

J Immunother Cancer
Soni S, Battaglin F, Castanon S, Yang Y, Smbatyan G, Torres Gonzalez L, Ho Lo J, Mittal P, Gonzalez E, Baugh AG, Soto Trujillo S, Ashouri K, Algaze S, Jayachandran P, Zhang W, K Singh I, Cerma K, Bergamo F, Lonardi S, Zhang Y, Kay SA, Yu J, Zhang L, Millstein J, T Roussos Torres E, Lenz HJ.   +25 more
europepmc   +1 more source

Thymine as potential biomarker to predict 5-FU systemic exposure in patients with gastro-intestinal cancer: a prospective pharmacokinetic study (FUUT-trial). [PDF]

Cancer Chemother Pharmacol
Hanrath MA, Banken E, van den Wildenberg SAH, van de Kerkhof D, Moes DJAR, Boisdron-Celle M, van den Bosch BJC, Bax R, Bet PM, Maring JG, Creemers GM, van Hellemond IEG, Deenen MJ.   +12 more
europepmc   +1 more source

Clinically actionable pharmacogenomic variants for anticancer therapy in Nigeria: first comprehensive variant profiling in underrepresented Nigerian cohorts. [PDF]

BMC Med Genomics
Ukpe MP, Ezeanuka AC.
europepmc   +1 more source

A call for reporting of tumor-specific outcomes in studies of DPYD genotyping. [PDF]

Clin Transl Sci
Ndayishimiye JD, Cayabyab M, Hoffecker G, Wittner V, Penn Medicine Biobank, Tuteja S.   +5 more
europepmc   +1 more source

Reply to "A call for reporting of tumor-specific outcomes in studies of DPYD genotyping". [PDF]

Clin Transl Sci
El Rouby N, Allen JD, Muldoon M, Beck M, Hesse K, Sebree N, Yoder R, Ritter S, Alqahtani Z, Grund J, Holbrook BP.   +10 more
europepmc   +1 more source

Precision Treatment of Patients With GI Cancer Using Pre-emptive <i>DPYD</i> Genotyping/Phenotyping Plus Pharmacokinetic-Guided Dosing of 5-Fluorouracil. [PDF]

JCO Precis Oncol
Fiebrich-Westra HB, Haroun C, van der Galiën R, den Besten-Bertholee D, Deenen MJ, Moes DJAR, Bet PM, de Groot JWB, Brohet RM, van Kuilenburg ABP, Maring JG.   +10 more
europepmc   +1 more source